2203-97-6
中文名稱
氫化可的松琥珀酸酯
英文名稱
Hydrocortisone 21-hemisuccinate
CAS
2203-97-6
分子式
C25H34O8
分子量
462.53
MOL 文件
2203-97-6.mol
更新日期
2024/12/25 19:46:27
2203-97-6 結(jié)構(gòu)式
基本信息
中文別名
氫可琥珀酸酯琥珀酸氫化可的松
氫化可的松琥珀酸酯
羥基可的松琥珀酸酯
氫化可的松氫琥珀酸鹽
氫化可的松半琥珀酸酯
氫化可的松半瑚珀酸酯
氫化可的松琥珀酸酯 1G
氫化可的松半琥珀酸酯無(wú)水
氫化可松琥珀氫 EP標(biāo)準(zhǔn)品
英文別名
C12888saxizon
NSC 7576
-2-oxoethoxy)
cortisolsuccinate
Hydrocortisone 21-he
CORTISOL HEMISUCCINATE
HYDROCORTISONE SUCCINATE
Hydrocortizone Succinate
CORTISOL 21-HEMISUCCINATE
所屬類別
原料藥：腎上腺皮質(zhì)激素類藥物理化學(xué)性質(zhì)
熔點(diǎn)170～172℃
比旋光度[α]D20 +147～+153° (c=1, C2H5OH) (After Drying)
沸點(diǎn)685.5±55.0 °C(Predicted)
密度1.33±0.1 g/cm3(Predicted)
儲(chǔ)存條件−20°C
溶解度Practically insoluble in water, freely soluble in acetone and in anhydrous ethanol. It dissolves in dilute solutions of alkali carbonates and alkali hydroxides.
酸度系數(shù)(pKa)pKa 5.10/5.64(20% aq EtOH/50% aq EtOH) (Uncertain)
形態(tài)neat
顏色白色至灰白色
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H360D
防范說(shuō)明P201-P202-P280-P308+P313-P405-P501
安全說(shuō)明22-24/25
WGK Germany3
RTECS號(hào)TU5010147
常見問(wèn)題列表
用途
氫化可的松琥珀酸酯是一種皮質(zhì)類固醇，用作分析和色譜試劑。
生物活性
Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate)，一種糖皮質(zhì)激素， 是口服活性的甾體抗炎劑 (SAID)。Hydrocortisone hemisuccinate 抑制 IL-6 和 IL-3 的生物活性，IC50 值分別為 6.7 和 21.4 μM。Hydrocortisone hemisuccinate 可用于潰瘍性結(jié)腸炎 (UC) 的研究。靶點(diǎn)
|
IL-6 6.7 μM (IC 50 ) |
IL-3 21.4 μM (IC 50 ) |
體外研究
Hydrocortisone hemisuccinate inhibits IL-6 and IL-3 bioactivity, with IC
50
s of 6.7 and 21.4 μM, respectively, and shows no cytotoxic effects on IL-6-independent MH60 cells.
Hydrocortisone hemisuccinate (0.12-60 μM; 72 h) inhibits phytohemagglutinin (PHA) response in peripheral lymphocytes (PBL) and T-lymphocytes cultures.
體內(nèi)研究
Hydrocortisone hemisuccinate (30 mg/kg; p.o. twice daily for 5 d) reduces the weight loss and increases the food intake in mice.
| Animal Model: | Male Sprague-Dawley rats (200-220 g, 10-11 weeks) are induced colitis |
| Dosage: | 30 mg/kg |
| Administration: | P.o. twice daily for 5 days |
| Result: |
Significantly decreased the disease activity index (DAI) scores and myeloperoxidase (MPO) activity compared to the 2, 4, 6-trinitrobenzenesulfonic acid (TNBS) group.
Increased the body weight. |